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current regulation and practices; (4) Lack of an ICER threshold. The likely future of 
health economic assessment of drugs in France will imply the expansion of health 
economic assessment scope, the implementation of an impactful ICER threshold, 
the generalisability of coverage with evidence, and eventually the possible merge 
of the CEESP and the CT. ConClusions: Major steps in French HTA are expected 
to occur in the near future. Empowerment of the CEESP (merged or not with the 
CT) is expected, and it may become the unique or leading committee addressing 
the HTA of pharmaceuticals in France. However, it is likely that the robust and well-
established methodology developed by the CT (SMR, ASMR) to assess comparative 
efficacy or effectiveness will remain in force.
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objeCtives: The National Centre for Pharmacoeconomics (NCPE) reviews the 
cost effectiveness of new medicines following an application for reimbursement 
in Ireland. All medicines are subjected to a preliminary rapid review (RR, stated 
to take ~2 weeks) with only high cost products and those with significant budget 
impact subjected to formal pharmacoeconomic assessments (PEA, stated to be com-
pleted in < 3 months). This research aims to review all recent NCPE appraisals to 
determine what proportion of drugs require a full appraisal, the review times and 
rates of approvals. Methods: Publically available decision summaries from the 
NCPE were identified (from 1st January 2013 to 31st May 2015) and the outcome, 
date, indication, and whether a full PEA was needed were extracted. Results: 110 
appraisals were identified with 43% (47/110) approved following RR. Of these, only 
21% (10/47) were reviewed within < 2 weeks; the rest taking on average > 2x longer 
than stated (29 days). Of the 57% (63/111) appraisals deemed to require a full PEA, 
62% (39/63) were initiated, on average, > 5 months post-RR. Only 33% (13/39) of full 
PEAs were eventually recommended, adding another 5 months (average 152 days) 
to the process. 27% (30/110) appraisals were for oncology medicines; 90% (27/30) of 
which required a full PEA. Only 15 were NCPE-appraised, almost all of which were 
not recommended (87%, 13/15). ConClusions: The total average length of time 
between start of the RR to final PEA recommendation is up to a year (12 months), 
which is substantially longer than what is claimed. If companies can convince the 
NCPE that their medicine is not high cost, nor has a significant budget impact, the 
RR process can enable rapid reimbursement within 1-2 months. However, if a full 
PEA is required, this significantly delays reimbursement decisions, with positive 
recommendations being difficult to achieve, especially for oncology medicines.
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objeCtives: The Swedish Dental and Pharmaceutical Benefits Agency (TLV) make 
recommendations on whether outpatient prescription drugs should be publically 
reimbursed with cost-effectiveness being a key criterion. By contrast, no national 
economic assessment was traditionally implemented for hospital pharmaceuticals, 
which were typically individually appraised by each county council. However, since 
January 2011, a national co-ordinating group of Swedish county councils (NLT) can 
request that selected in-patient therapies undergo a health economic assessment 
by the TLV, on which the NLT can conduct price negotiations and issue a national 
recommendation. This research aims to evaluate which drugs the NLT have been 
appraising and what the final outcomes were. Methods: A systematic search for all 
publically available NLT recommendation documents up to 1stMay 2015 was under-
taken and the drug, date, indication and recommendation, was extracted. Results: 
50 appraisal documents were identified, 54% (27/50) of which were recommended, 
16% (8/50) received restricted recommendations, 16% (8/50) rejected and 14% (7/50) 
classified as other (deferred/unclear). However, it is important to note that many of 
the drugs that were approved were not recommended at list price with 41% (11/27) of 
recommendations being conditional on or following a discount (including confidential 
discounts) and 11% (3/27) being based on an agreed risk sharing agreement. 2 apprais-
als were for ZOSTAVAX in shingles, which was previously reimbursed but, based on 
more recent data, was now deemed to no longer offer benefits that justified its costs. 
44% (22/50) appraisals were for oncology drugs only 1 (2%) of which was rejected 
(YERVOY, but was accepted upon resubmission). ConClusions: The NLT appears to 
have successfully implemented a process where significant price pressure is exerted 
on companies with discounts being frequently secured without being too restrictive 
over coverage. Could giving other cost-utility HTA bodies negotiating powers help 
bridge the gap between cost-containment and broadening coverage?
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objeCtives: Health technology assessment (HTA) is not deeply rooted in Finnish 
hospitals despite of long lasting attempts to introduce it into routine decision mak-
ing. Both the processes and content of the HTA approach have been challenged. 
The EU-funded AdHopHTA project has provided good practices and new tools for 
hospital based HTA. The aim of this study is to smoothen the introduction of these 
new tools by examining the obstacles HTA currently faces in hospitals. Methods: 
Semi-structured group interviews in five public hospitals and two health care cen-
tres. Interviewees were clinical unit managers, division managers, and financial 
or procurement managers. Questions were related to the process of proposing, 
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objeCtives: Chinese drug pricing reform initiated on 1stJune 2015 aims to create 
incentives for efficient management of drug reimbursement budget. This study aimed 
to assess the potential impact of the reform from the societal perspective. Methods: 
We conducted a thorough research on the drug pricing reform using three Chinese 
databases (CNKI, Wanfang, Weipu), Chinese health authorities’ websites, relevant 
press releases, pharmaceutical blogs and discussion forums. This research was com-
plemented with targeted interviews with Chinese key opinion leaders representing 
authorities’ and prescribers’ perspectives. Results: The reform may include intro-
duction of internal reference pricing (IRP) for drugs with the same active ingredient 
and dosage form. Therapeutic interchangeability of drugs is an important issue in 
China. Interviewed opinion leaders consistently agree that there are discrepancies 
in terms of quality between imported drugs and some locally produced generics. 
Introduction of IRP may promote the use of cheaper generics with questionable qual-
ity. Increased use of low-quality drugs may affect patients’ safety and treatment 
outcomes, and in turn lead to undesired increase of expenditures in other health-
care sectors. It could also increase inequity between different income groups if, as a 
result of increased co-payment, only the wealthiest could afford high-quality drugs. 
Additionally, the reform should not be implemented in isolation. Creating effective 
incentives for cost-containment without affecting healthcare quality requires global, 
rather than ‘micro-level’ focus. With hospitals being the main distributor of out-
patient drugs in China and economically depending on profit generated from drugs 
sales, pricing reform should be comprehensive and address restructuring of hospitals’ 
financing and management system. ConClusions: Before introducing the reform 
on a big scale, all local specificities and challenges should be properly addressed, e.g. 
the issue of poor-quality drugs. International reference pricing policies cannot be 
transferred to China without being adjusted for local context. To be successful, the 
reform requires a comprehensive approach.
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objeCtives: Since 2009, the Chinese government has launched a global healthcare 
reform program aiming to control healthcare expenditure and increase the quality of 
care. As a part of this program, a new drug pricing reform was initiated starting 1stJune 
2015. The objective of this study is to describe the changing landscape of drug pricing 
policy in China. Methods: We conducted a thorough research on drug pricing reform 
using three Chinese databases (CNKI, Wanfang, Weipu), Chinese health authorities’ 
websites, relevant press releases, pharmaceutical blogs and discussion forums. The 
secondary research was complemented with targeted interviews with Chinese key 
opinion leaders representing authorities’ and prescribers’ perspectives. Results: With 
the current reform, the government attempts to replace its direct control over prices 
of reimbursable drugs by an indirect influence. Government pricing and government 
guided pricing are abolished for most drugs giving manufacturers more freedom to set 
market prices. However, an introduction of a form of internal reference pricing (IRP), 
named ”reimbursement standard” has been announced. To inform the best approach 
for implementation of this reform, China is currently running pilot projects in several 
cities. Sanming is piloting a form of IRP for drugs with the same active ingredient and 
dosage form; it set the reference price at the price of the cheapest generic. Shaoxing and 
Anhui are testing the concept of “2nd price negotiation” allowing hospitals to directly 
negotiate discounts with manufacturers using provincial government procurement 
prices as reimbursement caps. First results of Sanming and Shaoxing pilots have 
already been reported, proving their potential for drug budget saving. ConClusions: 
Many elements of the reform remain unclear and will likely depend on pilot projects 
outcomes. It seems that the Chinese government is considering adaptation of IRP poli-
cies commonly used by European countries. However, foreign pricing policies cannot 
be transferred to China without being adjusted for local characteristics.
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objeCtives: The Economic and Public Health Assessment Committee (CEESP) was 
introduced in 2012 as a specialised committee affiliated with the ‘Haute Autorité 
de Santé’ (HAS) in charge of providing health economic opinions. This research 
provides a forward-looking analysis of health economic assessment of pharma-
ceuticals in France and its impact on market access of drugs. It also provides likely 
directions of the future French HTA organisation and processes. Methods: We 
conducted a grey literature search on the HAS website and decision makers’ public 
presentations and comments. This search was complemented with a meeting with 
experts in market access and health economics, HTA and public health to discuss 
the current functioning and the likely future path of health economic assessment 
in France. The main issues that emerged from the search and the discussion were 
consolidated and analysed. Results: Major sources of inefficiencies appeared fol-
lowing the introduction of health economic assessment: (1) Duplication of work 
between the CEESP and the CT; (2) Resolution of divergent opinions between the 
CEEPS and the CEPS; (3) Confusion and conflicting information with respect to the 
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process and identify any implications for manufacturers. Methods: Relevant county 
council and agency websites were used to gather insight into the new NT-rådet evalu-
ation process. A non-systematic literature review was conducted to identify infor-
mation illustrating potential implications of this new process. Results: NT-rådet 
selects in-patient drugs for centralised evaluation and specifies the degree to which 
treatment introduction will be centralised. For high priority treatments, Tandvårds-
och Läkemedelförmånsverket (TLV), will perform a health economic evaluation, upon 
which NT-rådet will base their recommendation, which will be accompanied by a 
monitoring protocol to ensure the organised introduction of treatments to all county 
councils. For low priority treatments, only a health economic evaluation and recom-
mendation will be issued. Any other treatments will go through decentralised reim-
bursement processes. NT-rådet plan to publish recommendations on approximately 
25 products or important indications per year. To date, NT-rådet has issued eight 
recommendations, including one joint recommendation for the use of six Hepatitis 
C therapies. This particular recommendation followed a first of its kind risk-sharing 
agreement between all 21 county councils and industry, which was a key product 
of this new process. ConClusions: The new assessment process has centralised 
the evaluation of some in-patient drugs, but not all. Most new treatments will still 
undergo the decentralised process. Due to its infancy, the impact of the NT-rådet 
process on the uptake of new expensive drugs remains to be confirmed.
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objeCtives: To understand the differences in time to launch between countries 
and the differences in time to reimbursement from launch Methods: We com-
pared time to launch as well as the time to reimbursement from launch of new 
molecular entities granted marketing authorization between 2009 and 2013 across 
18 developed countries. In addition, we conducted a sub-analysis comparing these 
measures for oncology and first-in-class medicines. A comprehensive analysis of the 
regulatory and market access landscapes was also assessed in order to understand 
the reasons behind any differences. Results: A large variation in time to launch of 
all new molecular entities (90 to 430 days) and time to reimbursement from launch 
was observed across studied countries (90 to 540 days). However, countries could be 
classified into three distinct groups: Countries with faster time to launch as well as 
faster time to reimbursement from launch - tended to have regulations mandating 
quick access, especially immediate coverage through public reimbursement after 
regulatory approval (e.g. Germany, Japan). Countries with faster time to launch, but 
slower time to reimbursement - had large private insurance markets but delayed 
public reimbursement negotiations (e.g. Canada). Countries with slower time to 
launch but fast reimbursement after launch - had almost exclusively public reim-
bursement but lengthy public reimbursement negotiations (e.g. France and Italy). 
Among the slower to launch countries, both first-in-class and oncology products 
achieved faster times to launch than the average across all new medicines. There 
was no difference observed in the fast launch countries. ConClusions: Time to 
launch and time to reimbursement from launch in a country is highly dependent 
on local market structure and market access regulations.
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objeCtives: Since 2013, Food and Drugs Administration (FDA) Breakthrough 
Therapy status has enabled expedited development and review of therapies where 
preliminary evidence suggests substantial clinical improvements for serious/life-
threatening conditions. However, there was a pre-existing FDA expedited pathway: 
Accelerated Approval enabling market entry of drugs for serious conditions based 
on a surrogate endpoint likely to predict clinical benefit with confirmatory tri-
als completed post-approval. This abstract aims to compare access of therapies 
under both pathways to determine in which distinct circumstances they are being 
used Methods: All FDA approvals from January 2013-March 2015 were screened 
for any approvals under Breakthrough Status and/or Accelerated Approval and 
the disease areas and supportive data packages were extracted. Results: Since 
November 2013, when the first therapy was approved under Breakthrough sta-
tus, 13 drugs have been FDA-approved under Accelerated Approval and 21 under 
Breakthrough Status including 8 supported by both expedited programs. For the 14 
approvals under Breakthrough Status alone, 11 (79%) were supported by Phase 3 data 
with the remaining 3 (21%) supported by Phase 2. Of the 6 drugs under Accelerated 
Approval alone, 2 (33%) were approved on Phase 3 data with the remaining 4 (66%) 
supported by Phase 2. Of the 7 approved under both programs, only 1 (14%) was 
supported by Phase 3 data, 4 (57%) by Phase 2 data and 2 (29%) by only Phase 1 
data. 86% (12/14) Breakthrough Status alone approvals were for non-oncology drugs 
versus just 16% (1/6) for Accelerated Approval alone and 0% (0/7) for under both pro-
grams. ConClusions: Whereas Accelerated Approval is typically used for oncology 
drugs, Breakthrough Status has been frequently applied to non-oncology medicines. 
Accelerated Approval also frequently enables expedited access without available 
supporting Phase 3 data, unlike Breakthrough Status. Products with supported by 
both programs have gained access supported by only Phase 1 data.
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evaluating, deciding and procuring new technologies. A mini-HTA sheet was tested 
during the interview and questions asked about the relevance and clarity of the 
questions. Results: The current processes of the uptake of technologies is rela-
tively similar in all studied hospitals. There are no standard, transparent evidence 
requirements, nor systems to assess and document the rationales for uptake. The 
clinicians report their needs in free format; the HTA-tools are not know nor used. 
After reducing the number of questions in the mini-HTA-sheet and making some 
changes to its content, order and terminology, the willingness to use increased. 
Information needed for budget impact analysis was considered of particular inter-
est. Procurement officials were strong proponents of systematic and transparent 
assessment. ConClusions: HTA tools need to be tailored to the hospitals. Instead 
of top-down requests for HTA, a low threshold tool is needed to document and 
justify the need of a new technology. This would pave the way for managers with 
financial responsibility to request more thorough assessments. This is the point 
where the new AdHopHTA tools could come in place.
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objeCtives: Telemedicine has been an innovation driver within e-health initiatives 
in health care in recent years. However, the uptake of such initiatives in Germany 
is low. Key question on that is if non-adequate reimbursement/funding might be 
the key reason for the slow introduction of e-health. Methods: We have reviewed 
German e-health initiatives and assessed the requirements for available reimburse-
ment pathways specifically for telemedicine initiatives in Germany and grouped 
them according to the application setting. Results: Overall there are currently 289 
e-health initiatives implemented in Germany in only few centers (mainly Berlin, Bad 
Oeynhausen, Munich, Hamburg). Telemedicine is being handled as medical devices 
in Germany within the market access pathway. The exact process depends if the 
device is an inpatient or outpatient product. In the inpatient setting relevant DRG 
and OPS codes are applicable; theoretically NUB and additional fee (Zusatzentgelt) 
could also be applied for. In the outpatient setting, the reimbursement of e-health 
devices is driven through the respective catalogue of aids and appliances whereas 
the actual physician service would need to be reimbursed through the EBM 
(Einheitlicher Bewertungsmassstab). Currently there is no specific EBM code avail-
able, and health politicians have missed a deadline in 2014 to create one. Besides the 
self-payment option as individual physicians services (IGeL) there is the opportunity 
through selective contracts, particularly Disease Management Programs (DMPs) or 
integrated care contracts. Most telemedicine projects are currently being covered 
and tested in the latter ones (e.g. telemonitoring CHF, video Parkinson therapy). An 
alternative new route could also be the experimental coverage by the joint federal 
committee. ConClusions: Currently the most relevant market access pathway 
for telemedicine initiatives in Germany is through selective contracts. Once health 
politicians put e-health as a priority the introduction of specific DRG and EBM 
codes could initiate fast adaption and more telemedine introductions in Germany.
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objeCtives: The British Isles comprise 4 countries, each with their own distinct 
Health Technology Assessment (HTA) body: National Institute of Health and Care 
Excellence (NICE) in England, National Centre for Pharmacoeconomics (NCPE) in 
Ireland, Scottish Medicines Consortium (SMC) in Scotland and All Wales Medicines 
Strategy Group (AWMSG) in Wales. Although all four bodies are obligate cost-utility 
HTA agencies, they do utilise distinct assessment processes. This research aims to 
compare the number and type of appraisals and recommendation rates between 
these bodies during 2014. Methods: All publically available NICE Single Technology 
Appraisal, SMC, NCPE and AWMSG HTA reports were identified in 2014 and the drug, 
indication and outcome extracted. Results: NCPE conducted the greatest number 
of appraisals (60) followed by the SMC (52), NICE (29) and the AWMSG (25). However, it 
should be noted that 68% of NCPE appraisals were through its rapid review pathway 
(not needing a full pharmaco-economic assessment). The highest rate of positive full 
recommendations was made by NICE (86%), followed by AWMSG (84%), SMC (79%), 
and the NCPE (39%). However, there was variation in what proportions of these 
recommendations were for a restricted sub-population: SMC (47%), AWMSG (29%), 
NICE (15%) and NCPE (5%). The proportion of oncology drugs appraised was highest 
by NICE (37%) followed by NCPE (37%), SMC (21%) and AWMSG (4%). ConClusions: 
The NCPE reviewed the greatest number of medicines but also had by far the highest 
rejection rates. Although NICE, AWMSG, and SMC had similar acceptance rates, the 
SMC displayed a greater propensity to restrict indications, and AWMSG (and to a 
lesser extent the SMC) reviewed a low number of oncology drugs, typically high cost 
agents that have greater difficulties in attaining positive reimbursement decisions. 
Thus it appears that in 2014 NICE appeared to be the most generous HTA body in 
awarding positive recommendations!
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objeCtives: The decision to fund an in-patient drug is currently made on a regional 
level by formulary committees in each of the 21 Swedish county councils. A pilot 
project for a centralised route of assessment for expensive, new in-patient treatments 
was replaced by a permanent body, Nya Terapier Rådet (NT-rådet), for centralised 
evaluation in January 2015. The objective of this research is to understand this new 
